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ABSTRACT - A patient presented with concurrent mood congruent delusions, 
parkinsonism, and elevated post-dexarnethacone plasma cortisol levels. Thi, triad 
could result from simultaneous development of cholinergic-monoaminergic dysfunc- 
tion within critical limbic and extrapyramidal loci. The magnitude of each abnor- 
mality decreased in concert during a course of electroconvulsive therapy (ECT). 
Remaining abnormalities disappeared during treatment with lithium. Actions of ECT 
and lithium on muscarinic systems are reviewed, and a strategy for testing the 
hypothesis that dysfunction of cholinergic-monoaminergic mechanisms develops in 
parallel in different neural networks i5  considered. 
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Endogenous depression and Parkinson’s disease 
may share neurotransmitter dysfunctions. In 
one major study 90% of all patients with Par- 
kinson’s disease had depressive symptomatology 
(1). Patients with parkinsonism or Parkinson’s 
disease also exhibit significantly increased fre- 
quencies of depressive symptoms compared to 
controls (2, 3). We present a patient with bipo- 
lar I disorder who exhibits the features of Par- 
kinson’s disease during depressive episodes. 
Severity of depression, parkinsonism and the 4 
p.m. Day I1 post dexamethasone plasma cor- 
tisol concentration decreased in parallel in the 
course of receiving consecutive treatment with 
electroconvulsive therapy (ECT) and lithium. 
Discussion focuses on the effects of ECT and 
lithium on the dynamics of cholinergic-mono- 
aminergic interaction. 
Case report 
Mrs. A, 59-year-old post-menopausal woman 
was admitted to the Clinical Studies Unit for 
Affective Disorders (CSU) at the University of 
Michigan Medical Center, with a 3-month hist- 
ory of depressed mood, anhedonia, loss of 
libido, social withdrawal, anergy, ruminations 
over previous real or imagined failures, hopeless- 
ness, suicidal ideation, early, middle, and termi- 
nal insomnia, anorexia, a 15 Ib. weight loss, 
constipation, difficulty concentrating, “inability 
to think,” marked retardation of speech and 
movement, and the conviction that she had 
uncontrollable diarrhea. She had three previous 
episodes of depression fulfilling Research Diag- 
nostic Criteria (RDC) (4) for major depressive 
disorder (MDD), endogenous subtype. Her first 
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episode, at 36, occurred post-partum. All epi- 
sodes responded well to ECT. She had at least 
one episode of mania by RDC for which she was 
treated with antipsychotic agents. She was 
asymptomatic for several years prior to admis- 
sion to the CSU. She fulfilled RDC for recurrent 
primary MDD, endogenous subtype with psy- 
chotic features, and bipolar 1 disorder, and also 
met DSM-I11 ( 5 )  criteria for bipolar affective 
disorder and MDD with melancholia and psy- 
chotic features. 
The referring internist and her family reported 
progressive bradykinesia, masked facies, ytooped 
posture, shuffling gate, and resting tremor in the 
course of the current episode. Two months follow- 
ing onset of depressed mood and extrapyramidal 
signs, amitriptyline hydrochloride, 75 mg q.h.s., 
thiothixene 5 mg q.h.s., and benztropine mesylate 
1 mg b.i.d. were started. These drugs were used 2 
weeks before presentation at the CSU. At that 
time all medications were discontinued in accor- 
dance with policies governing the diagnostic and 
research evaluation of CSU inpatients. No other 
psychotropics were used in the course of the cur- 
rent episode. Multiple interviews with relatives 
and Mrs. A's primary physician disclosed previous 
depressive episodes marked by bradykinesia, 
masked facies, stooped posture, shuffling gate, 
cogwheel rigidity and resting tremor, always 
resolving in the course of ECT. Signs of extra- 
pyramidal system dysfunction were not evident 
during her manic episode, even though it was 
treated with antipsychotics. Mrs. A was not treat- 
ed with antidepressants, antiparkinsonian-agents 
or lithium carbonate prior to the current episode. 
There was no family history of psychiatric or 
neurologic illness. 
The admission mental status examination 
revealed severe depression characterized by the 
previously noted signs and symptoms. The 17- 
item Hamilton Rating Scale for Depression 
HRSD) (6) score was 32. Her score was 20/30 on 
the mini-mental status examination (7). She 
failed on items demanding concentration, mem- 
ory, and duplication of visually presented fig- 
ures. Neurological examination revealed bra- 
dykinesia, cogwheel rigidity in all extremities, 
masked facies, stooped posture, shuffling and 
fenestrating gate, slowed, soft, monotonal 
speech, micrographia and pin-rolling tremor. 
There was no other evidence of extrapyramidal 
yystem dysfunction. 
The routine CSU laboratory screen includes a 
SMA-12, CBC and differential, urinalysis, serum 
VDRL,  vitamine B 12 and folate levels, deter- 
mination of tetraiodothyronine (TJ, triodo- 
thyronine (TJ, and thyroid stimulating hormone 
(TSH) levels by RIA, an electrocardiogram 
(EKG) and a chest radiogram. All results were 
within normal limits. A computerized axial 
tomographic (CAT) scan of the brain was also 
unremarkable. The admission dexamethasone 
suppression test (DST), conducted by the method 
of Carroll et al. (8), was positive. The 4 p.m. and 
11 p.m. post-dexamethasone cortisol levels were 
8.2 and 14.0 pg/dl, respectively. On the basis of 
historical information, cross-sectional assess- 
ment, and laboratory data, we concluded that 
Mrs. A had pseudodementia consequent to an 
endogenous depression (9). 
A 4-point global severity extrapyramidal signs 
scale (EPS) was completed every 7 days. The 
HRSD, EPS and DST were completed on the 
same day each week. HRSD and EPS ratings 
were completed at 4:OO p.m. so as to minimize 
variance due to circardian factors affecting 
mood, DST status, and motor activity. Rating 
scales were always completed by the same inves- 
tigator (R.S.J.), blind to DST results. Weekly 
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Fig. I. The plasma cortisol assay measures total plasma 
corticosteroids by the competitive protein binding tech- 
nique of Murphy (1967) as modified by Hsu and Bled- 
soe (1967) and Beardwell (1968). Intra-assay C.V. = 
6 .5%,  Intera-ssay C.V. = 12.5% when the mean plas- 
ma cortisol level is in the range of 2.5 pg/dl to 9 pg/dl 
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HRSD, 4 p.m. post-dexamethasone plasma cor- 
tisol levels and EPS ratings are presented in Fig. 
1 as a function of time in hospital. Note that 
days of ECT and lithium administration are 
specified. 
Atropine sulfate, given prior to induction of 
anesthesia, and thiopentol, employed as a gener- 
al anesthetic during ECT treatments, were the 
only psychoactive agents administered in hospital 
before starting lithium. Thiothixene, amitrip- 
tyline and benztropine were discontinued 5 weeks 
prior to starting the course of ECT during the 
4th week of hospitalization. During the evahla- 
tion phase, covering the first 3 weeks of hospital- 
ization, Mrs. A remained severely depressed and 
delusional. The EPS rating, 3 out of 4 (314) on 
admission, did not change prior to starting ECT. 
The highest 4 p.m. post-dexamethasone plasma 
cortisol level was 15.9 pg/dl. 
Mrs. A received nine bilateral, frontotemporal 
ECT treatments over 4 weeks. After the fifth 
treatment, she was no longer delusional and her 
HRSD score was 14. Bradykinesia, masked fac- 
ies, stooped postures, fenestrating gait, and res- 
ting tremor decreased. Nonetheless, the EPS 
score was 2/4 due to persisting mild bra- 
dykinesia, shuffling gait, and cogwheel rigidity. 
Both 4 p.m. and 11  p.m. post-dexamethasone 
levels were within normal limits (1.3 and 2.0 vg/ 
dl, respectively). Following the ninth ECT treat- 
ment, Mrs. A entered an operationally defined 
remission (HRSD score < 9). At this time, her 
HRSD score was 3 and she responded normally 
to challenge with dexamethasone. During the 7th 
week of hospitalization, Mrs. A’s EPS score was 
1/4 due to cogwheel rigidity in the upper 
extremities. 
Treatment with lithium was instituted during 
week 8, and by discharge at the end of week 10 
Mrs. A’s plasma lithium level was 0.92 mEq/l 
on a regime of 600 mg b.i.d. HRSD scores 
remained below 4 and there was no cognitive 
impairment. She scored 30/30 on the mini-men- 
tal status examination. Treatment with lithium 
was associated with a gradual disappearance of 
upper extremity cogwheel rigidity over a period 
of weeks. Discharge EPS score was 0/4. The 4 
p.m. post-dexamethasone plasma cortisol levels 
continued to be within normal limits during 
weeks 8-10, though two 1 1  p.m. levels (5.19 
and 14.37 pg/dl) were elevated during this 
period. 
One of us (S.C.D.) has been following Mrs. A 
since discharge 20 months ago. Lithium levels 
have fluctuated between 0.5 and 1 mEq/l .  She 
remains asymptomatic and without parkinson- 
ism. A DST done 3 months after discharge was 
within normal limits (4 p.m. post-dexamethasone 
cortisol level = 2.0 pg/dl). 
Discussion 
Covariation of depressive symptomatology, par- 
kinsonism, and post-dexamethasone plasma cor- 
tisol levels suggests the possibility of shared 
underlying mechanisms. Abnormalities of cho- 
linergic and dopaminergic systems are docu- 
mented characteristics of Parkinson’s disease 
(10) Parkinson’s disease is accompained by 
decreased brain and cerebral spinal fluid dopa- 
mine and dopamine metabolite concentrations 
(10). Endogenously depressed patients with 
psychomotor retardation exhibit this ( 1  1). Sero- 
tonergic and noradrenergic pathophysiology is 
involved in the etiology of basal ganglia disor- 
ders (12). Others have reported that endogenous 
depression is also marked by decreased turnover 
and synaptic activity of serotonin (13) and nor- 
epinephrine (14, 15). These points indicate that 
endogenous depression and parkinsonism involve 
similar disturbances of monoaminergic mecha- 
nisms. Serotonergic and noradrenergic (16) 
mechanisms may be involved in the 
pathophysiology of Parkinson’s disease via regu- 
lation of acetylcholine release from striatal cho- 
linergic neurons. Dilsaver & Greden (17) propose 
that similar mechanisms may be operative in 
mesolimbic regions involved in the regulation of 
mood and affect. Data indicate that endogenous 
depression and mania are associated with dys- 
function of cholinergic and monoaminergic sys- 
tems, or aberrant cholinergic-monoaminergic 
interaction in limbic regions involved in the reg- 
ulation of mood, drive reduction behavior, sleep 
onset, and staging and autonomic, neuroendo- 
crine and psychomotor functions. First, mus- 
carinic cholinergic system supersensitivity is 
implicated in the pathophysiology of the phe- 
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nomenologic aspects of affective disorders (18). 
Resistance to dexamethasone challenge may also 
involve this mechanism (19). This is consistent 
with observations indicating that physostigmine 
induces non-suppression to dexamethasone chal- 
lenge in normal subjects (20, 21). Risch and 
colleagues (22, 23) showed that affective disorder 
patients exhibit supersensitivity to physostig- 
mine-induced release of ACTH and b-endorphin 
compared to normal and psychiatric control sub- 
jects. Janowsky et al. (19) reported significant 
correlations between rises in absolute post-dex- 
amethasone plasma cortisol and ACTH levels, 
dysphoria and psychomotor retardation in sub- 
jects with MDD, endogenous subtype, during 
physostigmine infusion. 
Psychiatric and neuroscience reports emphas- 
ize effects of ECT and lithium on mono- 
aminergic networks. Holcomb et al. (24) 
described the progress of a patient with MDD, 
psychotic subtype (4), intra-episode parkinso- 
nism, and tardive dyskinesia during two courses 
of ECT. Mood and parkinsonism improved in 
parallel while tardive dyskinesia worsened. They 
reviewed 23 cases of patients with parkinsonism 
receiving ECT. Sixteen, including all with affec- 
tive illness, demonstrated a marked improvement 
in motor function. They concluded that this 
accords with the capacity of ECT to enhance the 
sensitivity of post-synaptic dopamine receptors 
and decrease the responsiveness of dopamine 
autoreceptors to dopamine agonists (25, 26). 
Pharmacologic agents which enhance the action 
of dopamine at central receptor sites, such as 
levo-dopa, bromocriptine, monoamine oxidase 
inhibitors, and tricyclic antidepressants (27-34) 
are effective in treating both endogenous depres- 
sion (7) and Parkinson’s disease. However, ECT, 
lithium and thymolytics modify noradrenergic 
( 1 9 ,  serotonergic ( 3 9 ,  and muscarinic cho- 
linergic (36-42) systems in addition to changing 
dopaminergic variables. Further, ECT (36-40) 
and lithium (41, 42) down-regulate cholinergic 
receptors. Lithium also prevents anticholinergic- 
induced muscarinic receptor up-regulation (42). 
ECT and lithium also increase the function of 
adrenergic, serotonergic and dopaminergic sys- 
tems. Treatments down-regulating muscarinic 
receptors, or diminishing the net activity of cho- 
linergic systems while potentiating monoami- 
nergic receptor function, should alleviate parkin- 
sonism. This, prima facie, conflicts with the 
efficacy of ECT and lithium in treating mania. 
However, lithium and ECT may stabilize, or 
render less perturbable, cholinergic and mono- 
aminergic systems. This may be essential to their 
clinical utility. 
Covariation of changes in depressive symp- 
toms, parkinsonism, and post-dexamethasone 
plasma cortisol levels, might be due to im- 
balances of cholinergic-monoaminergic systems 
at critical central loci systems which change in 
parallel. Quantifiable indices subject to cho- 
linergic-monoaminergic influences are: rate of 
salivary production, pupillary dynamics, body 
temperature, REM latency and density, and 
cGMP and phospholipid turnover (43). These 
and other physiological and biochemical end- 
points can be used to study cholinergic-mono- 
aminergic dynamics with standardized accurate 
methods of measurement. 
Patients exhibiting Mrs. A’s features may not 
be common but the anomalous and atypical 
often raise questions of greater heuristic value 
than does the mundane. Measurement of two or 
three physiological endpoints subject to cho- 
linergic and monoaminergic influences can ren- 
der the study of individual patients useful in 
testing specific hypotheses. 
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